High potency fish oil supplement improves omega-3 fatty acid status in healthy adults: an open-label study using a web-based, virtual platform

Nutrition Journal

Barry W Ritz¹  Jay K Udani² 

[1] 3Nutrition Sciences Department, College of Nursing and Health Professions, Drexel University, 245 N. 15th Street, Philadelphia, PA 19102, USA;Medicus Research, 28720 Roadside Drive, Suite 310, Agoura, CA 91301, USA

关键词: Open-label;    Fish oil;    Docosahexaenoic acid;    Eicosapentaenoic acid;    Omega-3 index;   

Others  :  805979
DOI  :  10.1186/1475-2891-12-112

 received in 2013-04-23, accepted in 2013-08-01,  发布年份 2013

【 摘 要 】

Background

The health benefits of omega-3 fatty acids from fish are well known, and fish oil supplements are used widely in a preventive manner to compensate the low intake in the general population. The aim of this open-label study was to determine if consumption of a high potency fish oil supplement could improve blood levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and impact SF-12 mental and physical health scores in healthy adults.

Methods

A novel virtual clinical research organization was used along with the HS-Omega-3 Index, a measure of EPA and DHA in red blood cell membranes expressed as a percentage of total fatty acids that has been shown to correlate with a reduction in cardiovascular and other risk factors. Briefly, adult subjects (mean age 44 years) were recruited from among U.S. health food store employees and supplemented with 1.1 g/d of omega-3 from fish oil (756 mg EPA, 228 mg DHA, Minami Nutrition® MorEPA® Platinum) for 120 days (n = 157).

Results

Omega-3 status and mental health scores increased with supplementation (p < 0.001), while physical health scores remained unchanged.

Conclusions

The use of a virtual, web-based platform shows considerable potential for engaging in clinical research with normal, healthy subjects. A high potency fish oil supplement may further improve omega-3 status in a healthy population regularly consuming an omega-3 supplement.

【 授权许可】

   
2013 Udani and Ritz; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, Cunnane SC, Holden JM, Klurfeld DM, Morris MC, Whelan J: Toward establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 2009, 139(4):S804-S819.
• [2]Buckley JD, Howe PRC: Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity – a review. Nutri 2010, 2:1212-1230.
• [3]Goldberg RB, Sabharwal AK: Fish oil in the treatment of dyslipidemia. Curr Opin Endocrinol Diabetes Obes 2008, 15:167-174.
• [4]Cabo J, Alonso R, Mata P: Omega-3 fatty acids and blood pressure? Br J Nutr 2012, 107(S2):195-200.
• [5]Djousse L, Biggs ML, Lemaitre RN, King IB, Song X, Ix JH, Mukamal KJ, Siscovick DS, Mozaffarian D: Plasma omega-3 fatty acids and incident diabetes in older adults. Am J Clin Nutr 2011, 94(2):527-533.
• [6]Nagata C, Takatsuka N, Shimizu H: Soy and fish oil intake and mortality in a Japanese community. Am J Epidemiol 2002, 156:824-831.
• [7]Hu FB, Cho E, Roxrode KM, Albert CM, Manson JE: Fish and long-chain ω-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003, 107:1852-1857.
• [8]Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885-1899.
• [9]Calder PC: n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci 2004, 107:1-11.
• [10]Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS: Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308(10):1024-1033.
• [11]Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B: Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2010, 5:808-818.
• [12]Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S: Fish, meat, and risk of dementia: cohort study. BMJ 2002, 325:932-933.
• [13]Lakhan SE, Vieira KF: Nutritional therapies for mental disorders. Nutr J 2008, 7:2. BioMed Central Full Text
• [14]Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L: Cognitive and physiological effects of omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest 2005, 35:691-699.
• [15]Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T: Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006, 56:159-164.
• [16]Solfrizzi V, Capurso C, D’Introno A, Colacicco AM, Frisardi V, Santamato A, Ranieri M, Fiore P, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F: Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment. J Nutr Health Aging 2008, 12(6):382-386.
• [17]Feart C, Peuchant E, Letenneur L, Samieri C, Montagnier D, Fourrier-Reglat A, Barberger-Gateau P: Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the three-City study. Am J Clin Nutr 2008, 87:1156-1162.
• [18]Ruxton CHS, Calder PC, Reed SC, Simpson MJA: The impact of long-chain n-3 polyunsaturated fatty acids on human health. Nutr Res Rev 2005, 18:113-129.
• [19]Ooyen C, Link C, Johnson J, Lynch E, Brush M, Rea P (Eds): Nutrition Business Journal’s 2012 Supplement Business Report. Boulder, CO: Penton Media Inc; 2012.
• [20]Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 2006, 47:2130-2139.
• [21]Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220-233.
• [22]Jenkinson C, Layte R, Jenkinson D, Lawrence K, Petersen S, Paice C, Stradling J: A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health Med 1997, 19(2):179-186.
• [23]Lim LL, Fisher JD: Use of the 12-item short-form (SF-12) health survey in an Australian heart and stroke population. Qual Life Res 1999, 8(1–2):1-8.
• [24]Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG: Dose–response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011, 93:243-252.
• [25]Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS: Omega-3 augmentation of sertraline in the treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009, 302(15):1651-1657.
• [26]Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS: n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the cardiovascular health study. Am J Clin Nutr 2003, 77:319-325.
• [27]Harris WS, Reid KJ, Sands SA, Spertus JA: Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am J Cardiol 2007, 99:154-188.
• [28]Harris WS, von Schacky C: The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 2004, 39:212-220.
• [29]von Schacky C: Use of red blood cell fatty-acid profiles as biomarkers in cardiac disease. Biomark Med 2009, 3(1):25-32.
• [30]Block RC, Dier U, Calderon Artero P, Shearer GC, Kakinami L, Larson MK, Harris WS, Georas S, Mousa SA: The effects of EPA + DHA and aspirin on inflammatory cytokines and angiogenesis factors. World J Cardiovasc Dis 2012, 2(1):14-19.
• [31]Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA: Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010, 303(3):250-257.
• [32]Utah Department of Health: 2001 Utah health status survey, interpreting the SF-12. http://www.health.utah.gov/opha/publications/2001hss/sf12/SF12_Interpreting.pdf webcite